View more press releases
Interim data show that AU-011 has been generally well-tolerated in the multiple ascending dose cohort of the ongoing clinical trial.
Interim data presented today show that AU-011 has been generally well-tolerated, and early efficacy results are very promising.
View more publications and presentations
Molecular Cancer TherapeuticsKines R, Varsavsky I, Choudhary S, Bhattacharya D, Spring S, McLaughlin R, Kang S, Grossniklaus H, Vavvas D, Monks S, MacDougall J, de los Pinos E, Schiller J
Nature EyeKaliki S and Shields C L
View more articles
Ten Bridge Communications